Literature DB >> 25650537

Delayed onset of benign pleural effusion following concurrent chemoradiotherapy for inoperable non-small-cell lung cancer.

R Kumar1, G Patel, G Kichenadasse, S Sukumaran, A Roy, B Koczwara, J J Bowden, J Leung, T Woo, C S Karapetis.   

Abstract

Chronic benign pleural effusion (BPE) is a rare complication of concurrent chemoradiotherapy (CRT) for inoperable stage IIIA non-small-cell lung cancer (NSCLC). This report presents three cases of BPE, the workup to differentiate this benign condition from recurrence of cancer and recommends a pleural biopsy as part of the diagnostic process. These inflammatory exudates often remain indolent, and may not require drainage or surgical intervention. In the absence of clinical, radiological and pathological evidence of recurrent disease, we recommend clinicians manage these patients expectantly, using regular clinical assessment and imaging.
© 2015 Royal Australasian College of Physicians.

Entities:  

Keywords:  benign pleural effusion; case series; concurrent chemoradiotherapy; non-small-cell lung cancer; stage III inoperable

Mesh:

Year:  2015        PMID: 25650537     DOI: 10.1111/imj.12658

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  2 in total

1.  Case report of delayed radiotherapy-related pleural effusion following chest radiotherapy for lymphoma.

Authors:  Panxiao Shen; Yunxiang Zeng; Weizhan Luo; Yingying Gu; Jinlin Wang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy.

Authors:  Matthew P Deek; Sairaman Nagarajan; Sinae Kim; Inaya Ahmed; Shiby Paul; Eli D Scher; Matthew Listo; Andrew Chen; Joseph Aisner; Sabiha Hussain; Bruce G Haffty; Salma K Jabbour
Journal:  Acta Oncol       Date:  2016-05-24       Impact factor: 4.089

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.